[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Shin EK, Takizawa BT, Masters L, Shahabi S: The role of chemotherapy and prophylactic bilateral oophorectomy in a case of colorectal adenocarcinoma with ovarian metastases. Yale J Biol Med; 2001 Mar-Apr;74(2):101-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy and prophylactic bilateral oophorectomy in a case of colorectal adenocarcinoma with ovarian metastases.
  • On exploratory laparotomy, the mass was found to be a moderately differentiated adenocarcinoma of the sigmoid colon with metastasis to the left ovary.
  • A primary colorectal carcinoma that has metastasized to the ovaries can be difficult to distinguish clinically from an advanced primary ovarian tumor.
  • If the nature of the primary tumor is uncertain and the initial response to chemotherapy is poor, the patient's prognosis will also he poor.
  • Though controversy exists regarding the role of prophylactic bilateral oophorectomy during resection for primary colorectal cancer, later confusion can be avoided by performing this procedure when the colorectal carcinoma is first diagnosed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Ovarian Neoplasms / secondary. Ovariectomy. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynaecol Obstet. 1994 Jul;46(1):39-43 [7805982.001]
  • [Cites] Acta Med Okayama. 1994 Feb;48(1):43-6 [8191916.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):124-8 [7557597.001]
  • [Cites] J Surg Oncol. 1995 Dec;60(4):268-76 [8551738.001]
  • [Cites] Orv Hetil. 1996 Oct 13;137(41):2249-51 [8992422.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):85-7 [8990444.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1299-302 [9369103.001]
  • [Cites] Dis Colon Rectum. 1998 Mar;41(3):277-83; discussion 283-5 [9514421.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):695-8 [9869515.001]
  • [Cites] Surg Clin North Am. 1974 Aug;54(4):881-6 [4428320.001]
  • [Cites] Dis Colon Rectum. 1977 Sep;20(6):506-10 [902546.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):827-30 [7302808.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):6-11 [6822165.001]
  • [Cites] J Clin Ultrasound. 1990 Nov-Dec;18(9):697-703 [2174920.001]
  • [Cites] Pediatr Radiol. 1991;21(7):531-2 [1663229.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):394-9 [1591052.001]
  • [Cites] Ann Chir. 1992;46(10):932-5 [1300907.001]
  • [Cites] Eur J Surg Oncol. 1993 Dec;19(6):633-5 [8270056.001]
  • [Cites] J Clin Ultrasound. 1994 Feb;22(2):121-5 [8132791.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S38-41 [7835808.001]
  • (PMID = 11393261.001).
  • [ISSN] 0044-0086
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2588692
  •  go-up   go-down


2. Huh JW, Park YA, Lee KY, Sohn SK: Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med J; 2009 Oct 31;50(5):697-703
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.
  • PURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer.
  • This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer.
  • MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA.
  • We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls.
  • Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma.
  • CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):405-8 [10684718.001]
  • [Cites] J Korean Med Sci. 2008 Oct;23(5):916-9 [18955806.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):369-75 [12782944.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):406-12 [15070089.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2159-64 [7074595.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24 [6428738.001]
  • [Cites] Recent Results Cancer Res. 1984;94:1-7 [6494573.001]
  • [Cites] Hematol Oncol. 1985 Jan-Mar;3(1):1-10 [2580768.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1283-95 [2429763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33 [3474637.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):191-204 [3410347.001]
  • [Cites] J Surg Oncol. 1989 Jan;40(1):4-7 [2909804.001]
  • [Cites] Eur J Cancer. 1991;27(10):1258-63 [1835595.001]
  • [Cites] J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29-34 [7762413.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):960-6 [9291821.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):27-35 [9652996.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):305-11 [9815986.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1625-31 [10334552.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):437-44 [10477162.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3453-9 [16101163.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):818-23 [16628000.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):449-53 [17180513.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • (PMID = 19881975.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ PMC2768246
  • [Keywords] NOTNLM ; Adenosine triphosphate / chemotherapy response assay / colorectal cancer
  •  go-up   go-down


3. Irshad K, Ahmad F, Morin JE, Mulder DS: Pulmonary metastases from colorectal cancer: 25 years of experience. Can J Surg; 2001 Jun;44(3):217-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastases from colorectal cancer: 25 years of experience.
  • OBJECTIVE: To examine the experience of pulmonary resections for colorectal metastases at the McGill University Health Centre.
  • PATIENTS: Forty-nine patients treated surgically between 1975 and 1998 for pulmonary metastases from colorectal cancer.
  • Significant preoperative variables that carried a poor prognosis included the following: more than one pulmonary lesion, a disease-free interval of less than 2 years, and moderately or poorly differentiated colorectal cancer.
  • The 16 patients who received chemotherapy after their thoracotomy had a 5-year survival rate of 51% compared with 54% for the 33 patients who did not receive chemotherapy.
  • CONCLUSIONS: Pulmonary resection for metastatic colorectal cancer is both effective and safe.
  • Postoperative chemotherapy has no survival benefit.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11407833.001).
  • [ISSN] 0008-428X
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3699122
  •  go-up   go-down


Advertisement
4. Kamoshita N, Makita F, Aiba M, Tokiniwa H, Nagashima T, Takeyoshi I, Ohwada S, Morishita Y: [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1187-90
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
  • We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy.
  • We diagnosed moderately-differentiated adenocarcinoma of the colon in two patients and of the rectum in two patients.
  • We recognized lymph node metastases in one patient and liver metastases in three patients at the time of operation.
  • After excision for a lesion of the colon or the rectum, all patients underwent a 2-week chemotherapy regimen (CPT-11 100 mg/m2/week + 5-FU 500 mg/m2/week + l-LV 10 mg/m2/week).
  • The progressive free survival time was 9.5 months and survival time ranged 5-18 months.
  • Grade 3 diarrhea and leukopenia were seen in one patient.
  • All other adverse reactions were mild (grade 1 or 2).
  • CPT-11/5-FU/l-LV combination chemotherapy appears to be effective for advanced and metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121927.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Peng YF, Gu J: Synchronous colorectal and lung cancer: report of three cases. World J Gastroenterol; 2008 Feb 14;14(6):969-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous colorectal and lung cancer: report of three cases.
  • The incidence of synchronous colorectal and lung cancer is relatively rare.
  • Pathological examination showed the colorectal cancer was a moderately differentiated adenocarcinoma and the lung cancer was a squamous cell carcinoma.
  • Surgical treatment and postoperative adjuvant chemotherapy for the lung cancer were different from those for colorectal cancer with pulmonary metastasis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Oct;217(1):257-61 [11012454.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Gut. 2002 May;50(5):647-52 [11950810.001]
  • [Cites] Int J Colorectal Dis. 2007 Jun;22(6):699-704 [17109105.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):155-62 [12871778.001]
  • [Cites] Dis Colon Rectum. 1993 May;36(5):425-9 [8482160.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):767-73 [12023581.001]
  • (PMID = 18240362.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687071
  •  go-up   go-down


6. Sheng LM, Zhang LZ, Xu HM, Zhu Y: Ascending colon adenocarcinoma with tonsillar metastasis: a case report and review of the literature. World J Gastroenterol; 2008 Dec 14;14(46):7138-40
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for colon adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ascending colon adenocarcinoma with tonsillar metastasis: a case report and review of the literature.
  • A 53-year-old man presented with painless left palatine tonsillar swelling and a cervical mass following right hemicolectomy for an ascending colon adenocarcinoma.
  • A punch biopsy was taken for histological examination which showed a moderately-differentiated adenocarcinoma.
  • The patient was treated with palliative radiotherapy and chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Colon, Ascending / pathology. Colonic Neoplasms / pathology. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / secondary
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Drug Therapy. Humans. Male. Middle Aged. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):328-30 [11373114.001]
  • [Cites] Nucl Med Rev Cent East Eur. 2007;10(1):12-5 [17694495.001]
  • [Cites] J Laryngol Otol. 1999 Nov;113(11):1036-8 [10696391.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2000 Aug;20(4):281-3 [11234447.001]
  • [Cites] J Laryngol Otol. 1971 Mar;85(3):289-92 [5576091.001]
  • [Cites] Otolaryngol Clin North Am. 1979 Feb;12(1):29-43 [220581.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1979 Mar-Apr;88(2 Pt 1):235-40 [443718.001]
  • [Cites] J Laryngol Otol. 1994 May;108(5):449-51 [8035134.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 Sep;58(3):209-12 [8940794.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Apr;116(4):563-4 [9141413.001]
  • [Cites] J Otolaryngol. 1997 Oct;26(5):325-6 [9343772.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):439-40 [10419718.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Sep;108(9):876-9 [10527279.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Jan;29(1):70-2 [15738898.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jul;5(2):108-13 [16098251.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Aug;53(8):455-7 [16164261.001]
  • [Cites] Auris Nasus Larynx. 2006 Mar;33(1):85-8 [16169179.001]
  • [Cites] Otolaryngol Pol. 2006;60(1):97-100 [16821552.001]
  • [Cites] J Otolaryngol. 2006 Aug;35(4):227-34 [17176797.001]
  • [Cites] Community Dent Oral Epidemiol. 2007 Apr;35(2):98-108 [17331151.001]
  • [Cites] Arch Bronconeumol. 2007 Jun;43(6):309-16 [17583640.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Nov;121(5):653-4 [10547490.001]
  • (PMID = 19084924.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC2776847
  •  go-up   go-down


7. Yamada T, Tanaka N, Yokoi K, Seya T, Kanazawa Y, Koizumi M, Ohaki Y, Tajiri T: Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. J Nippon Med Sch; 2008 Feb;75(1):23-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
  • The expression levels and activities of these three enzymes play important roles in the response of cancer patients to 5-FU-based chemotherapy.
  • PURPOSE: The purpose of this study was to investigate the relationship between the activities of 5-FU metabolic enzymes and clinicopathologic factors in colorectal cancer.
  • METHODS: We measured the activities of OPRT, DPD, and TS in colorectal cancer tissues.
  • We also investigated the correlations between the activities of these three enzymes and clinicopathologic factors (histological type, depth of tumor invasion, extent of lymph node metastasis, Dukes' stage, lymphatic invasion, and vascular invasion).
  • We examined 100 patients with surgically resected colorectal cancer.
  • RESULTS: Poorly differentiated adenocarcinoma showed significantly higher DPD activities than did moderately differentiated or well-differentiated adenocarcinoma.
  • No significant relation was found between TS activity and histological type, depth of tumor invasion, extent of lymph node metastasis, Dukes' stage, lymphatic invasion, or vascular invasion.
  • CONCLUSION: The response to 5-FU may be poor in patients with lymph-node metastasis, because of low OPRT activity, and in patients with poorly differentiated adenocarcinoma, because of high DPD activity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / enzymology. Fluorouracil / metabolism. Fluorouracil / therapeutic use. Orotate Phosphoribosyltransferase / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360075.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Hobdy EM, Ciesielski TE, Kummar S: Unusual sites of colorectal cancer metastasis. Clin Colorectal Cancer; 2003 May;3(1):54-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sites of colorectal cancer metastasis.
  • We present 2 separate cases of adenocarcinoma of the colon with metastasis to the chin and the bladder, both of which are unusual sites of colorectal cancer metastasis.
  • Patient 1 is a 77-year-old man who was diagnosed with adenocarcinoma of the colon, American Joint Committee on Cancer (AJCC) T4 N0 M0 (stage II), and underwent a right hemicolectomy.
  • Fourteen months later he developed a firm 2.5-cm mass involving the chin.
  • Excisional biopsy revealed moderately differentiated adenocarcinoma, consistent with the known colon primary tumor.
  • Patient 2 is a 75-year-old man who was diagnosed with AJCC T3 N1 M0 (stage III) adenocarcinoma of the colon and underwent sigmoid colectomy.
  • Ten years later, he was found to have transitional cell carcinoma involving retroperitoneal nodes with no identifiable bladder or ureteral primary, for which he received chemotherapy.
  • Eighteen months following this diagnosis, he developed hematuria and was found to have metastatic colon adenocarcinoma involving the bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12777193.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Pizzirusso F, Gillet JP, Fobe D: Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review. Acta Chir Belg; 2004 Apr;104(2):214-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review.
  • We present the case of a 66-year-old man with a moderately differentiated adenocarcinoma of the left colon and isolated spleen metastases, complicated with a gastrosplenic fistula.
  • The patient underwent a palliative segmental resection of the primitive colic tumour, as no curative treatment could be offered in view of the spleen involvement.
  • Adjuvant chemotherapy was started.
  • After a few chemotherapy treatments, he developed a gastrosplenic fistula which required the resection of the spleen and the greater gastric curvature together.
  • At the end of the chemotherapy course, all carcinologic features had also disappeared.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Gastric Fistula / etiology. Splenic Diseases / etiology. Splenic Neoplasms / secondary. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15154583.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 9
  •  go-up   go-down


10. Kravarusic D, Feigin E, Dlugy E, Steinberg R, Baazov A, Erez I, Lazar L, Kapuller V, Grunspan M, Ash S, Freud E: Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr; 2007 Feb;44(2):209-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma in childhood: a retrospective multicenter study.
  • OBJECTIVES: Colorectal carcinoma, a common adult malignancy, has an estimated childhood incidence of 0.3 to 1.5/million in Western countries and 0.2/million in Israel.
  • The aim of this multicenter study was to document the clinical profile, treatment and prognosis of colorectal carcinoma in children in Israel.
  • PATIENTS AND METHODS: The clinical, laboratory, therapeutic, and prognostic parameters of all 7 children from 4 medical centers in Israel who were diagnosed with colorectal carcinoma over a 25-y period were reviewed.
  • Average time to diagnosis was 6 months.
  • Six patients underwent surgery (1 refused), and 5 received chemotherapy.
  • Histopathological studies showed poorly differentiated mucinous adenocarcinoma, signet-ring type, in 4 cases, moderately differentiated adenocarcinoma in 2, and well-differentiated carcinoma in 1.
  • CONCLUSION: Colorectal carcinoma in children is characterized by aggressive tumor behavior and delayed diagnosis, resulting in a worse prognosis than in adults.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child, Preschool. Colectomy. Female. Humans. Israel. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255833.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Franceschi F, Fini L, Manno A, Carloni E, Zocco MA, Di Caro S, Picciocchi A, Coco C, Gasbarrini G, Gasbarrini A: Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3651

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis.
  • : 3651 Background: Several genes are differentially expressed during the multistep process of colorectal carcinogenesis.
  • Aim of the study was to identify the gene expression of colorectal adenocarcinoma tissues compared to the normal mucosa.
  • METHODS: RNA was extracted from 3 samples of moderately differentiated sporadic rectal adenocarcinoma and 3 samples of normal rectal mucosa obtained from the same patients and hybridized against the human U133A array set.
  • Gene expression of tumoral tissues and normal samples was compared; a minimum of 3 times fold differential expression among the same genes in neoplastic and normal samples was considered as significant.
  • Real-time PCR (Roche, Manheim) using the same RNA was also performed on a pool of either up- or down-regulated randomly-selected genes to validate the results.
  • 537 genes were upregulated while 13 genes were downregulated in neoplastic tissues.
  • The up-regulated genes included angiogenic factors (VEGF, PD-ECGF, EGF), markers of proliferation (PCNA), tumoral markers (CEA, ACE), genes involved in chemotherapy activity (Farnesyl-transferase, Topoisomerase-1) and several other genes of unclear function.
  • CONCLUSIONS: Colorectal cancer tissues show a different gene expression compared to the normal mucosa.
  • The identification of a panel of genes specifically expressed in neoplastic tisssues may provide a new tool for the molecular diagnosis of colorectal cancer and furnish new molecular targets for innovative therapeutical strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Takeda Y, Hasuike Y, Mishima H, Nishisho I, Kikkawa N: [Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer]. Gan To Kagaku Ryoho; 2000 Oct;27(12):1838-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
  • Hepatectomy has the highest cure rate among the various methods for treating liver metastasis from colorectal cancer.
  • In this study, we examined the efficacy of short-term continuous HAI of 5-FU for treating liver metastasis from colorectal cancer.
  • Computed tomography revealed a decrease of 55.6% in the size of the liver tumor.
  • Histological examination of the resected tumor showed marked degeneration, necrosis, fibrosis, and calcification with viable moderately differentiated adenocarcinoma cells.
  • These results suggest that preoperative HAI of 5-FU is safe and worth trying in patients with liver metastasis from colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11086425.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Chen WY, Mao WM, Zhao L, Chen GP, Shu Y, Shen YF, Zhu XH, Xia Y: [Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2005 Dec;27(12):738-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance].
  • OBJECTIVE: To study the expression and clinical significance of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers.
  • METHODS: The expression of P-gp, GST-pi and Topo II alpha in 83 cases with gastric or colorectal cancer were examined by immunohistochemistry S-P.
  • RESULTS: The positive expression rates of P-gp, GST-pi, Topo II alpha in normal tissue and gastric and colorectal cancers were 69.9%, 65.1%, 50.6% and 83.1%, 85.5%, 45.8%, respectively.
  • The positive rates of P-gp and GST-pi in gastric and colorectal cancer were significantly higher than those in normal gastric and colorectal tissue (P < 0.05).
  • The expression of Topo II alpha in poorly differentiated cancers was significantly higher than that in well-and moderately differentiated cancers.
  • CONCLUSION: P-gp, GST-pi and Topo II alpha play important role in multidrug resistance.
  • Their mechanisms of drug resistance were different.
  • The detection of expression of P-gp, GST-pi and Topo II alpha has an important guiding significance in chemotherapy for gastric and colorectal cancers.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Drug Resistance, Neoplasm. Gastrointestinal Neoplasms / metabolism. Glutathione S-Transferase pi / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Stomach Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483485.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / P-Glycoprotein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


14. Katsumata K, Ichimiya H, Wakana Y, Okada K, Kato K, Aoki T: [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Apr;31(4):623-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
  • We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin.
  • Case 1 was a 40-year-old man with rectal carcinoma (moderately differentiated adenocarcinoma; se, n1, p1, H0, stage IV).
  • He underwent low anterior resection of the rectum and postoperatively showed an increase peritoneal dissemination and liver metastasis.
  • As of 30 months post-treatment the patient was alive.
  • Case 2 was a 60-year-old man with rectal carcinoma (well differentiated adenocarcinoma; ss, n1, p0, H1, stage IV).
  • He underwent low anterior resection and postoperatively was given 3 courses of fluorouracil and l-Leucovorin.
  • Adverse drug reactions in both patients were controlled on an outpatient basis.
  • While in the past liver metastasis has been treated by hepatic arterial infusion chemotherapy, a combination therapy with fluorouracil and l-Leucovorin can be used on an outpatient basis and results in a favorable response.
  • This suggests that this combination therapy has clinical significance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Middle Aged. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114713.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H: High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol; 2009 Apr 28;15(16):2016-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy.
  • AIM: To investigate the ezrin expression in normal colorectal mucosa and colorectal cancer tissues, and study the correlation between ezrin expression in colorectal cancer tissues and tumor invasion and metastasis.
  • METHODS: Eighty paraffin-embedded cancer tissue samples were selected from primary colorectal adenocarcinoma.
  • Twenty-eight patients had well-differentiated, 22 had moderately differentiated and 30 had poorly differentiated adenocarcinoma.
  • Another 22 paraffin-embedded tissue blocks of normal colorectal epithelium (> 5 cm away from the edge of the tumor) were selected as the control group.
  • All patients with colorectal cancer were treated surgically and diagnosed histologically, without preoperative chemotherapy or radiotherapy.
  • The immunohistochemistry was used to detect the ezrin expression in paraffin-embedded normal colorectal mucosa tissues and colorectal cancer tissue samples.
  • RESULTS: Ezrin expression in colorectal cancer was significantly higher than in normal colorectal mucosa (75.00% vs 9.09%, P < 0.01), and there was a close relationship between ezrin expression and the degree of tumor differentiation, lymph node metastasis and Dukes stage (88.46% vs 50.00%, P < 0.01; 94.28% vs 51.11%, P < 0.01; 94.28% vs 51.11%, P < 0.01).
  • CONCLUSION: Ezrin expression is obviously higher in colorectal cancer tissues than in normal colorectal mucosa tissues, and the high level of ezrin expression is closely related to the colorectal cancer invasion and metastasis process.
  • [MeSH-major] Colorectal Neoplasms. Cytoskeletal Proteins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Maturitas. 2008 May 20;60(1):31-41 [18486367.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):273-81 [12893187.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Microvasc Res. 2004 Jan;67(1):18-28 [14709399.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):113-4 [14998486.001]
  • [Cites] Urology. 2004 Mar;63(3):609-12 [15028477.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):201-4 [15121044.001]
  • [Cites] Trends Mol Med. 2004 Jun;10(6):249-50 [15177187.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):7224-9 [8636161.001]
  • [Cites] J Pathol. 1996 May;179(1):74-9 [8691349.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1231-7 [8808697.001]
  • [Cites] EMBO J. 1997 Jan 2;16(1):35-43 [9009265.001]
  • [Cites] Trends Biochem Sci. 1996 Dec;21(12):455-8 [9009824.001]
  • [Cites] Curr Biol. 1997 Sep 1;7(9):682-8 [9285722.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):885-95 [9472040.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 10;258(2):395-400 [10329398.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R365-73 [15987432.001]
  • [Cites] Apoptosis. 2005 Oct;10(5):941-7 [16151629.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3629-38 [16585188.001]
  • [Cites] Infect Immun. 2007 Dec;75(12):5669-77 [17908813.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):55-63 [18155831.001]
  • [Cites] Ai Zheng. 2008 Feb;27(2):165-9 [18279614.001]
  • [Cites] J Cell Sci. 2008 Mar 1;121(Pt 5):644-54 [18270268.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):752-6 [17886294.001]
  • [Cites] Pol J Pathol. 2007;58(4):235-43 [18459457.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2181-91 [12802084.001]
  • (PMID = 19399936.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC2675094
  •  go-up   go-down


16. Li LN, Zhang HD, Yuan SJ, Yang DX, Wang L, Sun ZX: Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur J Pharmacol; 2008 Jun 24;588(1):1-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin.
  • In the present investigation, we compared the anticancer effects of artesunate on three colorectal cancer cell lines and analyzed the relationship between drug sensitivity and malignant phenotype of the tumor cells.
  • The findings are as follows: poorly-differentiated was colorectal cancer cell line CLY showing nuclear beta-catenin accumulation and loss of E-cadherin; moderately-differentiated were Lovo cells with cytoplasmic distribution of the two proteins; and well-differentiated were HT-29 cells with membranous localization of them.
  • Also, both in vitro and in vivo, poorly- or moderately-differentiated CLY and Lovo were more susceptible to artesunate treatment than well-differentiated HT-29.
  • Due to the vital roles of Wnt pathway and the epithelial to mesenchymal transition in tumor differentiation, we thought artesunate could promote the re-differentiation and apoptosis of colorectal cancer cells by inhibition of hyperactive Wnt pathway and reversion of the epithelial to mesenchymal transition.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Agents. Artemisinins / pharmacology. Cadherins / biosynthesis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. beta Catenin / biosynthesis
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Flow Cytometry. Fluorescent Antibody Technique, Indirect. Humans. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Proteins / biosynthesis. Subcellular Fractions / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448095.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Artemisinins; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / beta Catenin; 60W3249T9M / artesunate
  •  go-up   go-down


17. Neagoe A, Chira O, Zaharia T, Cruciat C: Education and management of patients with familial adenomatous polyposis. Are we making progress? A case report. Rom J Gastroenterol; 2004 Dec;13(4):333-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The family history revealed two deaths due to colorectal cancer (maternal grandmother and patient's mother).
  • Histopathological diagnosis revealed moderately differentiated adenocarcinoma.
  • Adjuvant chemotherapy was carried out.
  • Two of them were diagnosed with adenomatous polyposis - the first with classic FAP and the other one with the attenuated type (AFAP).
  • Screening and prophylactic surgery are effective to prevent colorectal cancer in patients with FAP.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli. Colorectal Neoplasms / pathology. Patient Education as Topic

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624032.001).
  • [ISSN] 1221-4167
  • [Journal-full-title] Romanian journal of gastroenterology
  • [ISO-abbreviation] Rom J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 18
  •  go-up   go-down


18. Sugimoto S, Noura S, Seki Y, Ohue M, Motoori M, Goto K, Kishi K, Eguchi H, Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O, Tanaka E, Nishiyama K: [A case of metastatic liver cancer from rectal cancer demonstrating a clinical CR with 3D-CRT]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2171-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 62-year-old man who underwent a low anterior resection for rectal cancer.
  • The tumor was a moderately differentiated adenocarcinoma, type 2 in the Japanese classification of colorectal carcinoma.
  • He did not receive any adjuvant chemotherapy.
  • The patient refused a surgery and chemotherapy.
  • He was given a total dose of 60 Gy/10 fractions/10 days with 3D-CRT.
  • At 19 months from the radio therapy, the disease was diagnosed as CR because no tumors were detected.
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed


19. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, it was a moderately differentiated adenocarcinoma with a biopsy examination.
  • The patient was followed by 8 courses of adjuvant chemotherapy with 5-FU.
  • Usually the prognoses of Stage IV colorectal cancer patients are very unpleasant.
  • Even thougn a few patients with Stage IV colorectal cancer can be a long-term survivor after multiple operations, we need to consider carefully the indication of the operation and QOL for a Stage IV colorectal cancer patient.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Colectomy. Fluorouracil / therapeutic use. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Kömürcü S, Ozet A, Oztürk B, Arpaci F, Altundağ MK, Tezcan Y: Colon cancer during pregnancy. A case report. J Reprod Med; 2001 Jan;46(1):75-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of colorectal carcinoma in pregnancy was 1 per 13,000 liveborn deliveries during 1981-1989.
  • Histologic examination confirmed serosal and lymph node invasion of moderately differentiated mucous-secreting adenocarcinoma of the cecum and adenocarcinoma metastatic to the liver.
  • The patient received systemic chemotherapy.
  • Women with colorectal carcinoma during pregnancy usually have a poor prognosis, which may be attributable to younger age and delay in diagnosis since the initial symptoms often are presumed attributed to normal pregnancy, as in this case.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cesarean Section. Embolization, Therapeutic. Fatal Outcome. Female. Gestational Age. Hepatic Artery. Humans. Liver Neoplasms / secondary. Pregnancy. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11209639.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A: EGFR expression in gallbladder carcinoma in North America. Int J Med Sci; 2008;5(5):285-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Increased epidermal growth factor receptor (EGF receptor) expression has been noted in various cancers and has become a useful target for therapeutic interventions.
  • Eight patients had poorly differentiated adenocarcinoma, six had moderately differentiated and two had well-differentiated tumors.
  • In this small series, there was a trend toward shorter survival and more poorly differentiated tumors in patients with greater intensity of EGFR expression.
  • CONCLUSION: In view of our observations confirming the over-expression of EGFR in our patient population in North America, and the recent success of EGFR targeted therapies in other solid tumors that over-express EGFR, it may now be appropriate to evaluate agents targeting this pathway either as single agents or in combination with standard chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. North America. Receptor, ErbB-2 / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2112-7 [18378567.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6971-6 [11585718.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4089-91 [11600613.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):96-100 [11823707.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] Ai Zheng. 2003 Mar;22(3):262-5 [12654182.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):174-7 [12714891.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):265-81 [14598145.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1516-20 [15083178.001]
  • [Cites] Korean J Gastroenterol. 2005 Jan;45(1):52-9 [15665568.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] J Pathol. 2005 Jul;206(3):356-65 [15892172.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):724-34 [16229013.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):634-6 [16467552.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1680-5 [16551849.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):127-31 [16601429.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):111-6 [18473995.001]
  • [Cites] Oncology. 2007;72(1-2):105-10 [18025804.001]
  • [Cites] Ann Oncol. 2004 May;15(5):765-9 [15111344.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):346-50 [14997381.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Oncology. 1994 Sep-Oct;51(5):396-400 [8052479.001]
  • [Cites] Eur J Cancer. 1995 Sep;31A(10):1594-8 [7488407.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1087-91 [8822109.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2257-60 [10472340.001]
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):565-9 [15577433.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):907-13 [16648872.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] BMC Cancer. 2006;6:190 [16846514.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Clin Colorectal Cancer. 2006 Nov;6(4):265-72 [17241511.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):319-24 [17551313.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3202-9 [17705089.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] Am J Clin Oncol. 2008 Apr;31(2):140-4 [18391597.001]
  • [Cites] Rev Recent Clin Trials. 2006 Jan;1(1):1-13 [18393776.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 18825277.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2556051
  • [Keywords] NOTNLM ; differentiation / endothelial growth factor receptor (EGFR) / gallbladder cancer / her-2-neu / survival
  •  go-up   go-down






Advertisement